EU BioPharma Clinical Trials: Key Oncology Data at ASCO & AUA
Key BioPharma clinical trial updates are expected at major conferences in 2026, including ASCO, AUA, and BioPharma Clinical Trials Nexus, focusing on oncology trials.
Key Takeaways
- Several late-breaking abstracts and key presentations are scheduled for major BioPharma clinical trials conferences in 2026.
- Key events include the ASCO Annual Meeting, AUA Annual Meeting, and BioPharma Clinical Trials Nexus.
- Focus on oncology trials with Phase 3 topline results, Phase 2 interim data, and Phase 1 updates.
Several significant BioPharma clinical trial updates are expected to be presented at major conferences in 2026, including the ASCO Annual Meeting, the AUA Annual Meeting, and the BioPharma Clinical Trials Nexus. These presentations will cover a range of oncology trials, featuring Phase 3 topline results, Phase 2 interim data, and Phase 1 updates.
The upcoming conferences will provide a platform for researchers and industry professionals to discuss the latest advancements in cancer treatment and clinical trial strategies. These events are crucial for understanding the evolving landscape of BioPharma and its impact on patient care.
ImPact Biotech: Padeliporfin VTP Data
ImPact Biotech will present updated data from the Phase 3 ENLIGHTED trial of padeliporfin (brand name not available) vascular-targeted photodynamic (VTP) therapy for low-grade upper tract urothelial carcinoma (LG UTUC). Preliminary Phase 1 data for padeliporfin VTP in locally advanced pancreatic ductal adenocarcinoma (LA-PDAC) will also be presented. These presentations are scheduled for both the ASCO and AUA meetings. Topline data from the ENLIGHTED trial is expected in 2026, followed by a potential NDA submission.
Kelun-Biotech: NSCLC and Solid Tumor Updates
Kelun-Biotech will have three oral presentations at the ASCO Annual Meeting. These include data on sacituzumab tirumotecan (sac-TMT) (brand name not available) with pembrolizumab versus pembrolizumab monotherapy in PD-L1-positive advanced non-small cell lung cancer (NSCLC) from the Phase III OptiTROP-Lung05 trial (Abstract Number: 8506, Session: May 29, 3:12–3:24 PM CDT). Additionally, data on lunbotinib fumarate (A400/EP0031) (brand name not available), a next-generation selective RET inhibitor, for advanced RET fusion-positive NSCLC from a Phase II pivotal study (Abstract Number: 8505, Session: May 29, 2:36–2:48 PM CDT) will be presented. Finally, an update on SKB500, a novel antibody-drug conjugate (ADC), for locally advanced or metastatic solid tumors from an open-label, first-in-human study will be shared.
BioPharma Clinical Trials Nexus
The BioPharma Clinical Trials Nexus conference, held in Zurich on April 29–30, 2026, will feature panel discussions, roundtables, poster presentations, and 1:1 meetings focused on clinical trial operations and strategy.
Market & Investor Implications
The data presented at these conferences could significantly impact the market and investor sentiment for ImPact Biotech and Kelun-Biotech. Positive results from the ENLIGHTED trial and the Kelun-Biotech NSCLC studies could lead to increased investor confidence and potential stock price appreciation.
What to Watch Next
The key focus will be on the detailed data releases from the ASCO and AUA meetings, particularly the Phase 3 results for padeliporfin VTP and the Phase 3 trial (OptiTROP-Lung05) of sacituzumab tirumotecan. Further updates from the BioPharma Clinical Trials Nexus regarding innovative clinical trial strategies will also be closely monitored.
Frequently Asked Questions
-
What are the key conferences for BioPharma clinical trial data in 2026?
The key conferences include the ASCO Annual Meeting, AUA Annual Meeting, and BioPharma Clinical Trials Nexus.
-
What data is ImPact Biotech presenting?
ImPact Biotech is presenting updated data from the Phase 3 ENLIGHTED trial for LG UTUC and preliminary Phase 1 data for LA-PDAC.
-
What is Kelun-Biotech presenting at ASCO?
Kelun-Biotech is presenting data on sacituzumab tirumotecan with pembrolizumab for NSCLC, lunbotinib fumarate for RET fusion-positive NSCLC, and SKB500 for solid tumors.
-
What is the focus of the BioPharma Clinical Trials Nexus conference?
The conference focuses on clinical trial operations and strategy.
